This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Theratechnologies

Stocks in this article: TH.TO ARNA VVUS OSIR AMRN GSK MELA

BOSTON ( TheStreet) -- Theratechnologies (TH.TO) received approval Thursday for a new drug, Egrifta, which reduces abdominal fat in HIV-infected patients. Via Twitter, @cookyourassets opens this week's Biotech Stock Mailbag asking for my thoughts on Theratechnologies now that Egrifta was approved.

Egrifta's U.S. marketing clearance is great news for Theratechnologies, although much of the upside was baked into the stock, illustrated by the positive but relatively muted reaction Thursday.

FDA approved Egrifta for the reduction of abdominal fat in HIV-infected patients, a condition known as lipodystrophy that is a common side effect of antiretroviral drugs used to treat HIV.

Theratechnologies shares on the Toronto Stock Exchange were up about 9% to $5.47 intraday Thursday. You'd expect more from a small stock with a new drug approval but the big, 80%-plus upside move came last May after an FDA advisory panel unanimously backed Egrifta's approval.

Egrifta will be sold in the U.S. by EMD Serono, an affiliate of the German drug firm Merck KGaA, through a partnership under which Theratechnologies receives royalty payments based on Egrifta sales. A $25 million milestone paid to Theratechnologies upon Egrifta's approval will largely cover the company's 2011 expenses.

Egrifta is the first approved therapy for abdominal lipodystrophy but the drug's label is not without risk and limitations. Whether Egrifta decreases the risk of cardiovascular disease or improves compliance with antitretroviral drugs has not been studied.

On the safety side, Egrifta stimulates certain cellular growth factors and increases blood sugar levels, so FDA warns doctors to be cautious about treating patients with a history of cancer and asks that blood sugar levels be monitored. Egrifta must also be injected once a day, which may be a convenience challenge for HIV patients accustomed to daily pills.

Egrifta has some commercial challenges, which likely also explains Thursday's muted stock reaction. BMO Capital analyst Jason Zhang sees upside in Theratechnologies to $8-9 a share, if U.S. sales of Egrifta can reach $200-$250 million in 2013 (with royalty revenue of around $41 million flowing to Theratechnologies.)


Arena Pharmaceuticals (ARNA) shareholders this week called me a thief, an insidious crook, a fool, a hedge fund puppet, an embarrassment, a shill for the shorts, a pathetic pawn of the hedge funds, a liar, a nerd, a basher, a hack, a joke and an idiot.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs